^
PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
anlotinib + sintilimab
Sensitive
:
C4
Onco Targets Ther - 2wk
NTRK3 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
C3
ISPOR 2021 - 3wk
NTRK2 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
C3
ISPOR 2021 - 3wk
NTRK1 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
C3
ISPOR 2021 - 3wk
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Anaplastic Carcinoma
CaT
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
cisplatin
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
docetaxel + doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
paclitaxel
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
A2
RET mutation
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive
:
A2
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
carboplatin + paclitaxel
Sensitive
:
A2
RET fusion
Thyroid Gland Anaplastic Carcinoma
pralsetinib
Sensitive
:
A2
EGFR L858R
Thyroid Gland Anaplastic Carcinoma
erlotinib
Sensitive
:
C1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
vemurafenib
Resistant
:
C1
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
PLX8394 + cobicistat
Sensitive
:
C3
PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
pembrolizumab + lenvatinib
Sensitive
:
C3
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab + lenvatinib
Sensitive
:
C3
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
vemurafenib + atezolizumab
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our